News & Trends - Pharmaceuticals
First study to show alcohol and tobacco policies reduced cancer deaths in Australia

Policies aimed at cutting alcohol and tobacco consumption, including the introduction of random breath testing programs and bans on cigarette advertising, have resulted in a significant reduction in Australian cancer death rates, new research shows.
The La Trobe Centre for Alcohol Policy Research (CAPR) has led the first study into how public health policies on alcohol and tobacco implemented from the 1960s affected cancer deaths in Australia.
Researchers led by La Trobe epidemiologist Dr Jason (Heng) Jiang compared cancer mortality data available from the 1950s with historical alcohol and tobacco control policies and 100-years of consumption data.
Dr Jiang said the results are a century in the making.
“Our research provides new evidence that key public health policies on alcohol and tobacco introduced in Australia from the 1960s to 2013 are related to reductions in mortality rates for various cancers,” Dr Jiang said.
“The changes in mortality rates are measured over 20-year periods and emphasise that the effects of alcohol and tobacco policies cannot be fully evaluated in the short-term.
“It’s clear from our findings that the full effect of more recent policies, such as plain cigarette packaging and alcohol content labelling of beverages, may not be known for decades.”
Enhance visibility and amplify your company’s brand value to Pharma, MedTech and Biotech subscribers. Contact us.
Published today in BMC Medicine, the researchers found:
• A series of key health policies on alcohol and tobacco have prevented more than 5 per cent (36,000) of total cancer deaths in Australia between the 1960s and 2013
• The introduction of random breath testing programs in Australia in 1976 was associated with a reduction in population drinking and cancer death rates for both men and women. The policy prevented 1 per cent of male deaths (4880) and 0.8 per cent of female deaths (1680) overall between the 1980s and 2013
• The release of UK and US public health reports in 1962 and 1964 on the health effects of tobacco was associated with a reduction in Australian tobacco consumption and cancer death rates – excluding liver cancer – with 3 per cent of male (13,400) and 4 per cent of female cancer deaths (11,600) in Australia in the last 30 years
• The ban on cigarette advertising on Australian TV and radio in 1976 was associated with a 1.9 (4,520) and 2.2 (2,430) per cent reduction in total male and female cancer death rates respectively, excluding liver cancer, between the 1980s and 2013
• Liquor license liberalisation introduced in the 1960s was linked to an increase of 0.6 per cent (2,680) of total male cancer deaths in the last 30 years
Dr Jiang said the study should help inform future government campaigns or policies on alcohol and tobacco.
“It’s important to evaluate what works, what doesn’t, and where to invest future funding,” Dr Jiang said.
“We hope these findings will also help Australians make more informed decisions on their alcohol and tobacco consumption.”
Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.
News & Trends - MedTech & Diagnostics

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms
Hospitals shouldn’t be forced to grovel to private health insurers to secure funding for essential, lifesaving medical devices. But thanks […]
MoreNews & Trends - Pharmaceuticals

Oncologists pioneer liquid biopsy-guided treatment in lung cancer
Lung cancer is Australia’s leading cause of cancer deaths. Local experts are set to lead a new frontier in personalised […]
MoreMedical and Science

The high cost of record low research funding
Australia has delivered some of the world’s most transformative health and medical breakthroughs – the cochlear implant, the HPV vaccine, […]
MoreNews & Trends - Pharmaceuticals

UCB secures dermatology indication with first dual IL-17A/F inhibitor
UCB’s IL-17A and IL-17F inhibitor has been added to the Australian Register of Therapeutic Goods (ARTG) for adults with moderate […]
More